Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ZNTL 
Zentalis Pharmaceuticals Llc (ZNTL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ZNTL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $6.19
1 Year Target Price $6.19
| 3 | Strong Buy |
| 1 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -66.57% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 112.53M USD | Price to earnings Ratio - | 1Y Target Price 6.19 |
Price to earnings Ratio - | 1Y Target Price 6.19 | ||
Volume (30-day avg) 10 | Beta 1.77 | 52 Weeks Range 1.01 - 4.44 | Updated Date 10/18/2025 |
52 Weeks Range 1.01 - 4.44 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.28 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -638.12% |
Management Effectiveness
Return on Assets (TTM) -25.41% | Return on Equity (TTM) -49.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -145996149 | Price to Sales(TTM) 4.19 |
Enterprise Value -145996149 | Price to Sales(TTM) 4.19 | ||
Enterprise Value to Revenue 7.77 | Enterprise Value to EBITDA -2.31 | Shares Outstanding 72135453 | Shares Floating 49978327 |
Shares Outstanding 72135453 | Shares Floating 49978327 | ||
Percent Insiders 13.54 | Percent Institutions 72.72 |
Upturn AI SWOT
Zentalis Pharmaceuticals Llc
Company Overview
History and Background
Zentalis Pharmaceuticals, LLC is a biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancer. Founded in 2014.
Core Business Areas
- Discovery and Development: Focus on identifying and developing small molecule therapeutics for cancer treatment.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates.
Leadership and Structure
Kimberly Blackwell, MD, is the CEO of Zentalis. The company has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- ZN-c3: An oral WEE1 inhibitor in Phase 2 trials for various advanced solid tumors. Its competitors are AstraZeneca's Adavosertib and other WEE1 inhibitors under development. Revenue is currently preclinical.
- ZN-d6: A selective EGFR inhibitor in Phase 1/2 trials for EGFR-driven cancers. Competitors include AstraZeneca's Tagrisso and other EGFR inhibitors. Revenue is currently preclinical.
Market Dynamics
Industry Overview
The oncology drug market is a large and rapidly growing market driven by increasing cancer incidence and advancements in treatment options.
Positioning
Zentalis is a clinical-stage biopharmaceutical company focused on developing differentiated small molecule therapeutics. They aim to address unmet needs in cancer treatment.
Total Addressable Market (TAM)
The global oncology market is expected to reach hundreds of billions of dollars. Zentalis is positioned to capture a portion of this TAM with their targeted therapies, assuming successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Strong pipeline of clinical-stage assets
- Experienced management team
- Focus on validated oncology targets
- Proprietary drug discovery platform
Weaknesses
- Dependence on clinical trial success
- Limited commercialization experience
- High cash burn rate
- Reliance on external funding
Opportunities
- Potential for partnerships and collaborations
- Expansion of pipeline through new drug candidates
- Regulatory approvals for lead assets
- Increasing demand for targeted cancer therapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- AZN
- MRTX
- LLY
Competitive Landscape
Zentalis competes with both large pharmaceutical companies and smaller biotech companies in the oncology space. Their advantage lies in their focus on specific targets and differentiated drug candidates. Their disadvantage is their lack of commercialization experience and reliance on external funding.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by advancement of drug candidates through clinical trials.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and potential commercialization or partnerships. Analyst estimates should be consulted for specific revenue and earnings projections.
Recent Initiatives: Recent initiatives include advancing ZN-c3 and ZN-d6 in clinical trials and expanding the pipeline with new drug candidates.
Summary
Zentalis is a clinical-stage biopharmaceutical company with a promising pipeline of oncology drugs. Its success hinges on the outcome of clinical trials. While the company has a strong focus and experienced team, it faces significant risks related to clinical development, competition, and funding. The company does not have products on the market, therefore revenue is nearly 0.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is based on publicly available information and may not be completely accurate or up-to-date. Market share estimates are approximate. Investing in biopharmaceutical companies involves significant risks, including clinical trial failures and regulatory hurdles.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zentalis Pharmaceuticals Llc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-04-03 | CEO, President & Director Ms. Julie M. Eastland M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 166 | Website https://zentalis.com |
Full time employees 166 | Website https://zentalis.com | ||
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.